公开(公告)号：US20230338532A1

公开(公告)日：2023-10-26

申请号：US18044429

申请日：2021-09-10

Applicant: NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Antonio BERTOLETTI ,  Anthony Tanoto TAN ,  Morteza HAFEZI

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N9/16 ,  C12N9/04

CPC classification number: A61K39/4632 ,  A61K39/4611 ,  A61K39/4622 ,  A61K39/464463 ,  A61K39/464454 ,  A61K39/464838 ,  A61P35/00 ,  C07K14/7051 ,  C12N9/16 ,  C12Y301/03016 ,  C12N9/0006 ,  C12Y101/01205 ,  A61K2239/53

Abstract: Described are novel immunosuppressant drug resistant armored (IDRA) T cells that co-express an exogenous T cell receptor (TCR) and one or more exogenous inhibitors of an immunosuppressant. The TCR can bind to an antigen expressed by a tumor cell or virally infected cell. Also described are methods of producing the modified T cell, and methods of treating a subject using the modified T cells.

公开(公告)号：US20230265479A1

公开(公告)日：2023-08-24

申请号：US18017967

申请日：2021-08-03

Applicant: EUKARYS

Inventor： Philippe JAIS

IPC: C12P21/02 ,  C12N9/16 ,  C12N9/10 ,  C12N9/12 ,  C12N15/85 ,  C12N15/52

CPC classification number: C12P21/02 ,  C12N9/16 ,  C12Y301/03016 ,  C12N9/104 ,  C12N9/1247 ,  C12N15/85 ,  C12N15/52 ,  C12N2800/107

Abstract: The present invention concerns a method for expressing a recombinant DNA molecule in a eukaryotic host cell, comprising the steps of:



(a) expressing or introducing at least one chimeric protein, in said host cell, wherein said chimeric protein comprises:

(i) at least one catalytic domain of a capping enzyme, in particular selected in the group consisting of cap-0 canonical capping enzymes, cap-0 non-canonical capping enzymes, cap-1 capping enzymes and cap-2 capping enzymes; and
(ii) at least one catalytic domain of a DNA-dependent RNA polymerase, in particular a bacteriophage DNA-dependent RNA polymerase,


(b) constitutively or transiently downregulating the phosphorylation level of subunit a of translation initiation factor eIF2 (eIF2α) in said host cell.




The invention also concerns an isolated nucleic acid molecule or a set of nucleic acid molecules, comprising or consisting of (1) at least one nucleic acid sequence encoding a chimeric protein comprising at least one catalytic domain of a capping enzyme; and at least one catalytic domain of a DNA-dependent RNA polymerase; and (2) at least one nucleic acid sequence downregulating the phosphorylation level of eIF2α in a eukaryotic host cell or encoding a polypeptide downregulating said phosphorylation level; and (3) optionally, at least one nucleic acid sequence encoding a poly(A) polymerase, as well as vectors, kits and cells comprising said nucleic acid molecule or set, and different uses and applications thereof.

公开(公告)号：US09914922B2

公开(公告)日：2018-03-13

申请号：US14395780

申请日：2013-04-22

Applicant: Ionis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Eric E. Swayze

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/11 ,  C12N15/113

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/343 ,  C12N2310/3525 ,  C12N2320/51 ,  C12Y301/03016 ,  C12Y301/03048 ,  C12Y301/03067

Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

公开(公告)号：US20180066241A1

公开(公告)日：2018-03-08

申请号：US15556229

申请日：2016-03-31

Applicant: Universite Pierre Et Marie Curie (Paris 6) ,  Institut National De La Sante Et De La Recherche Medicale ,  Consejo Superior De Investigaciones Cientificas ,  Katholieke Universiteit Leuven

Inventor： Angelita Rebollo Garcia ,  Jeronimo Bravo Sicilia ,  Jesus Maria Fominaya Gutierrez ,  Etienne Waelkens ,  Veerle Janssens

IPC: C12N9/16 ,  C07K14/47 ,  C07K7/06 ,  C07K7/08

CPC classification number: C12N9/16 ,  A61K38/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4702 ,  C07K2319/01 ,  C07K2319/10 ,  C07K2319/70 ,  C12Y301/03016

Abstract: The invention provide chimeric peptides comprising a chimeric peptide comprising a cell-penetrating peptide linked to a pro-apoptotic peptide, wherein the pro-apoptotic peptide is derived from, or consists of, a portion of PP2A protein that binds a SET protein or is derived from, or consists of, a portion of the SET protein that binds PP2A protein.

公开(公告)号：US20160237114A1

公开(公告)日：2016-08-18

申请号：US15044393

申请日：2016-02-16

Applicant: PURDUE RESEARCH FOUNDATION

Inventor： Tamara Lea Kinzer-Ursem ,  Chethana Kulkarni ,  Julia Grace Fraseur

IPC: C07K1/22 ,  C07K14/47

CPC classification number: C07K1/22 ,  C12N9/16 ,  C12Y301/03016

Abstract: Disclosed herein are protein enrichment substrates and methods for making the same that can be used to enrich proteins of interest. Also disclosed herein are methods for protein purification using these protein enrichment substrates.

Abstract translation: 本文公开了蛋白质富集底物及其制备方法，其可用于富集感兴趣的蛋白质。 本文还公开了使用这些蛋白质富集底物的蛋白质纯化的方法。

公开(公告)号：US20150184153A1

公开(公告)日：2015-07-02

申请号：US14395780

申请日：2013-04-22

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Eric E. Swayze

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/343 ,  C12N2310/3525 ,  C12N2320/51 ,  C12Y301/03016 ,  C12Y301/03048 ,  C12Y301/03067

Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Abstract translation: 本发明提供低聚化合物。 某些这样的寡聚化合物可用于与互补核酸杂交，包括但不限于细胞中的核酸。 在某些实施方案中，杂交导致细胞中靶核酸的活性或表达的调节。

公开(公告)号：US20120156180A1

公开(公告)日：2012-06-21

申请号：US13390073

申请日：2010-08-10

Applicant: Ernesto Bongarzone

Inventor： Ernesto Bongarzone

IPC: A61K48/00 ,  C07K14/145 ,  C07D211/32 ,  A61P25/28 ,  A61K38/08 ,  A61K31/445 ,  A61K35/12 ,  C07H21/02 ,  C07K7/06

CPC classification number: A61K31/7088 ,  A61K31/4458 ,  A61K31/52 ,  A61K35/28 ,  A61K38/005 ,  A61K38/08 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3513 ,  C12Y207/10002 ,  C12Y207/11001 ,  C12Y207/11013 ,  C12Y207/11022 ,  C12Y207/11024 ,  C12Y207/11026 ,  C12Y301/03016 ,  C12Y301/03048 ,  C12Y304/22052 ,  C12Y304/22053 ,  C12Y304/22056

Abstract: Provided are compositions and methods for the treatment of Krabbe and other neurodegenerative diseases, including storage diseases such as GM1 gangliosidosis, Niemann-Pick disease, Tay-Sachs disease, Sandhoff disease, metachromatic leukodystrophy, Canavan disease, Pelizaeus-Merzbacher disease, and storage conditions facilitated by aging of lysosomal functions, which are associated with psychosine (and/or other storage material)-mediated axonal degeneration. Compositions and methods employ (1) one or more inhibitor of a phos-photransferase activity of one or more kinase(s) such as, for example, CDK5, P38, jnk, src, CK2, PKC, GSK3α and β; (2) one or more inhibitor of a phosphotransferase activity of one or more phosphatase(s) such as, for example, the Ser/Thr protein phosphatase PP1 and Tyr protein phosphatase PP2; one or more inhibitor of a caspase/calpain activity of one or more caspases such as caspase 3 and calpains such as calpain 1 and 2; and (4) one or more inhibitor of a sodium/calcium exchange protein such as, for example, NCX1. Inhibitors include small molecules, including the GSK3β inhibitor L803 and the NCX1 inhibitor flecainide, and siRNA molecules that downmodulate cellular levels of one or more mRNA, including siRNA that are capable of downmodulating the cellular expression of PP1. Inhibitors disclosed can cross the blood-brain barrier and, thus, are available to the central nervous system (CNS) and effective in reducing psychosine-mediated axonal degeneration.

Abstract translation: 提供了用于治疗Krabbe和其它神经变性疾病的组合物和方法，包括存储疾病如GM1神经节苷脂病，尼曼皮克病，泰萨病，桑德霍夫病，异染色性脑白质营养不良症，卡纳万病，Pelizaeus-Merzbacher病和储存条件 通过与精神病（和/或其他储存材料）介导的轴索变性相关的溶酶体功能的老化促进。 组合物和方法使用（1）一种或多种一种或多种激酶（例如CDK5，P38，jnk，src，CK2，PKC，GSK3α和bgr）的磷酸转移酶活性的抑制剂。 （2）一种或多种一种或多种磷酸酶的磷酸转移酶活性的抑制剂，例如Ser / Thr蛋白磷酸酶PP1和Tyr蛋白磷酸酶PP2; 一种或多种胱天蛋白酶/钙蛋白酶活性的一种或多种胱天蛋白酶抑制剂，例如胱天蛋白酶3和钙蛋白酶如钙蛋白酶1和2; 和（4）一种或多种钠/钙交换蛋白抑制剂，例如NCX1。 抑制剂包括小分子，包括GSK3＆bgr; 抑制剂L803和NCX1抑制剂flecainide，以及下调调节一种或多种mRNA的细胞水平的siRNA分子，包括能够下调PP1细胞表达的siRNA。 所公开的抑制剂可以穿过血脑屏障，因此可用于中枢神经系统（CNS），并有效减少精神病介导的轴索变性。

公开(公告)号：US20080138347A1

公开(公告)日：2008-06-12

申请号：US11866369

申请日：2007-10-02

Applicant: Ralf M. LUCHE ,  Bo WEI

Inventor： Ralf M. LUCHE ,  Bo WEI

IPC: A61K39/00 ,  C07K16/00 ,  G01N33/53 ,  C12Q1/68 ,  C12N5/04 ,  A61K38/00

CPC classification number: C12Q1/42 ,  A61K38/00 ,  C12N9/16 ,  C12Y301/03016 ,  C12Y301/03048 ,  G01N33/573 ,  G01N2500/04

Abstract: Compositions and methods are provided for the treatment of conditions associated with cell proliferation, cell differentiation and cell survival. In particular, the dual-specificity phosphatase DSP-10, and polypeptide variants thereof that stimulate dephosphorylation of DSP-10 substrates, are provided. The polypeptides may be used, for example, to identify antibodies and other agents that inhibit DSP-10 activity. The polypeptides and agents may be used to modulate cell proliferation, differentiation, and survival.

Abstract translation: 提供组合物和方法用于治疗与细胞增殖，细胞分化和细胞存活相关的病症。 特别地，提供了刺激DSP-10底物去磷酸化的双特异性磷酸酶DSP-10及其多肽变体。 多肽可用于例如鉴定抑制DSP-10活性的抗体和其它试剂。 多肽和试剂可用于调节细胞增殖，分化和存活。

公开(公告)号：US07384761B2

公开(公告)日：2008-06-10

申请号：US10220375

申请日：2001-03-02

Applicant: Ying Luo ,  Xiang Xu

Inventor： Ying Luo ,  Xiang Xu

IPC: C12Q1/48 ,  C12N9/16

CPC classification number: C07K14/4738 ,  C12N9/16 ,  C12Y301/03016 ,  G01N33/5011 ,  G01N33/6872 ,  G01N2333/4739 ,  G01N2333/8114

Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

Abstract translation: 本发明涉及对细胞周期有影响或与细胞周期有关的新型多肽，核酸和相关分子。 本文还提供了与异源多肽序列融合的本发明的载体和宿主细胞多肽，与本发明的多肽结合的抗体和用于产生本发明的多肽的方法。 本发明还提供了鉴定介导细胞周期生物活性的新型组合物的方法，以及这些组合物在疾病诊断和治疗中的应用。

公开(公告)号：US20060275758A1

公开(公告)日：2006-12-07

申请号：US10519336

申请日：2003-06-20

Applicant: Daniel Cohen ,  Iiya Chumakov ,  Marta Blumenfeld ,  Sanober Shaikh ,  Marta Palicio-Barron ,  Hadi Abderrahim ,  Pascale Grel

Inventor： Daniel Cohen ,  Iiya Chumakov ,  Marta Blumenfeld ,  Sanober Shaikh ,  Marta Palicio-Barron ,  Hadi Abderrahim ,  Pascale Grel

IPC: C12Q1/68 ,  G01N33/53 ,  C12Q1/42 ,  C12P19/34

CPC classification number: C12Q1/42 ,  A61K48/00 ,  C07K14/705 ,  C12N9/16 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Y301/03016 ,  G01N33/573 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/916 ,  G01N2500/04 ,  G01N2800/302 ,  G01N2800/304

Abstract: The invention relates to the use of PP2A/Bγ and to the use of a PP2A phosphatase comprising the PP2A/Bγ subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The invention also discloses biallelic markers located in the gene encoding PP2A/Bγ and their use for diagnosing mental disorders.

Abstract translation: 本发明涉及PP2A / Bgamma的用途以及包含PP2A / Bgamma亚基的PP2A磷酸酶用于筛选其调节剂的用途。 进一步公开了使用这些调节剂来治疗诸如双相性精神障碍，精神分裂症和抑郁症的精神障碍和包含这些调节剂的药物。 本发明还公开了位于编码PP2A / Bgamma的基因中的双重标记及其用于诊断精神障碍的用途。